View in EDS HTML Full Text PDF Full Text

Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a real-world retrospective study.

Saved in:
Bibliographic Details
Title: Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a real-world retrospective study.
Authors: Gao J; The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China., Xu J; Postgraduate College, Xuzhou Medical University, Xuzhou, China., He Y; Postgraduate College, Xuzhou Medical University, Xuzhou, China., Zong D; The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China., Jin T; The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China., He X; The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China.
Source: Frontiers in oncology [Front Oncol] 2025 Nov 06; Vol. 15, pp. 1624286. Date of Electronic Publication: 2025 Nov 06 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41278271
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a real-world retrospective study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gao+J%22">Gao J</searchLink>; The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China.<br /><searchLink fieldCode="AU" term="%22Xu+J%22">Xu J</searchLink>; Postgraduate College, Xuzhou Medical University, Xuzhou, China.<br /><searchLink fieldCode="AU" term="%22He+Y%22">He Y</searchLink>; Postgraduate College, Xuzhou Medical University, Xuzhou, China.<br /><searchLink fieldCode="AU" term="%22Zong+D%22">Zong D</searchLink>; The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China.<br /><searchLink fieldCode="AU" term="%22Jin+T%22">Jin T</searchLink>; The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China.<br /><searchLink fieldCode="AU" term="%22He+X%22">He X</searchLink>; The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2025 Nov 06; Vol. 15, pp. 1624286. <i>Date of Electronic Publication: </i>2025 Nov 06 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41278271
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2025.1624286
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1624286
    Titles:
      – TitleFull: Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a real-world retrospective study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gao J
      – PersonEntity:
          Name:
            NameFull: Xu J
      – PersonEntity:
          Name:
            NameFull: He Y
      – PersonEntity:
          Name:
            NameFull: Zong D
      – PersonEntity:
          Name:
            NameFull: Jin T
      – PersonEntity:
          Name:
            NameFull: He X
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 06
              M: 11
              Text: 2025 Nov 06
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 15
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1